Source 1primary paper2026MED
Toolkit/Domain III chimerization
Domain III chimerization
Also known as: Cry1A.105
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Countermeasures now integrate ... Domain III chimerization (e.g., Cry1A.105)
Usefulness & Problems
Why this is useful
Domain III chimerization is presented as a toxin engineering strategy, with Cry1A.105 given as an example. The abstract places it among next-generation countermeasures for resistance.; engineering resistance-breaking toxin variants
Source:
Domain III chimerization is presented as a toxin engineering strategy, with Cry1A.105 given as an example. The abstract places it among next-generation countermeasures for resistance.
Source:
engineering resistance-breaking toxin variants
Problem solved
It is intended to generate resistance-breaking variants when field-evolved resistance reduces efficacy of existing Bt Cry toxins.; redesigning Bt toxins to overcome resistance
Source:
It is intended to generate resistance-breaking variants when field-evolved resistance reduces efficacy of existing Bt Cry toxins.
Source:
redesigning Bt toxins to overcome resistance
Problem links
redesigning Bt toxins to overcome resistance
LiteratureIt is intended to generate resistance-breaking variants when field-evolved resistance reduces efficacy of existing Bt Cry toxins.
Source:
It is intended to generate resistance-breaking variants when field-evolved resistance reduces efficacy of existing Bt Cry toxins.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
domain swappingTarget processes
editingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
This strategy requires the ability to redesign and construct chimeric toxin variants.; requires toxin domain engineering
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Next-generation countermeasures for Bt resistance include synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization, PACE, and AlphaFold3-guided rational redesign.
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Approval Evidence
1 source1 linked approval claimfirst-pass slug domain-iii-chimerization
Countermeasures now integrate ... Domain III chimerization (e.g., Cry1A.105)
Source:
engineering strategysupports
Next-generation countermeasures for Bt resistance include synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization, PACE, and AlphaFold3-guided rational redesign.
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Source:
Comparisons
Source-stated alternatives
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Source:
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Source-backed strengths
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Source:
Countermeasures now integrate synergistic Cry/Vip pyramiding, CRISPR/Cas9-validated receptor knockouts revealing functional redundancy, Domain III chimerization (e.g., Cry1A.105), phage-assisted continuous evolution (PACE), and the emerging application of AlphaFold3 for structure-guided rational redesign of resistance-breaking variants.
Compared with CRISPR/Cas9
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Compared with CRISPR/Cas9 system
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Compared with Cry/Vip pyramiding
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Shared frame: source-stated alternative in extracted literature
Source:
The abstract mentions Cry/Vip pyramiding, CRISPR/Cas9 receptor knockouts, PACE, and AlphaFold3-guided redesign as related approaches.
Ranked Citations
- 1.